Treatment of malignant diseases using lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity: Experimental research

Yasuhiko Kimoto, Minehide Lee-Miyamoto, Shin ichiro Takai, Haidong M Dong, Tetsuo Taguchi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Peripheral blood lymphocytes (PBL) possess lectin-dependent cellular cytotoxicity (LDCC) in the presence of various lectins. In this study we showed more potent LDCC could be induced in lymphokine-activated killer (LAK) cells. Among several lectins investigated in this study pokeweed mitogen (PWM) could give LAK cells most potent and broad spectrum LDCC when LAK cells were initially stimulated by PWM. Analysis of effector cells revealed that either PBL, CD3+CD4+, CD 3+CD 8+ cells or CD3-CD56+ cells expressed manifest cytotoxicity in the presence of lectins. Both anti-HLA class I and anti-HLA class II monoclonal antibodies did not inhibit LDCC at any concentrations applied. Taken together with the former result, HLA, CD 3, CD 8 or CD 56 molecules were not relevant to LDCC. Quality and quantity of binding sites were shown to be different between effector cells and target tumor cells revealed by FACS analysis using fluorescence conjugated PWM. Mechanism of LDCC partially associated with apoptotic cell death but without NO production by effector cells. These facts suggest that more potent immunotherapy of malignant diseases might be applicable using mechanism of LDCC.

Original languageEnglish (US)
Pages (from-to)188-198
Number of pages11
JournalJapanese Journal of Clinical Immunology
Volume17
Issue number3
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
Lectins
Research
Pokeweed Mitogens
Therapeutics
Lymphocytes
Immunotherapy
Cell Death
Fluorescence
Binding Sites
Monoclonal Antibodies

Keywords

  • Immunotherapy
  • LAK cell
  • LDCC

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Treatment of malignant diseases using lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity : Experimental research. / Kimoto, Yasuhiko; Lee-Miyamoto, Minehide; Takai, Shin ichiro; Dong, Haidong M; Taguchi, Tetsuo.

In: Japanese Journal of Clinical Immunology, Vol. 17, No. 3, 1994, p. 188-198.

Research output: Contribution to journalArticle

Kimoto, Yasuhiko ; Lee-Miyamoto, Minehide ; Takai, Shin ichiro ; Dong, Haidong M ; Taguchi, Tetsuo. / Treatment of malignant diseases using lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity : Experimental research. In: Japanese Journal of Clinical Immunology. 1994 ; Vol. 17, No. 3. pp. 188-198.
@article{c3f3a09a453941ffac0c5d9127d51e38,
title = "Treatment of malignant diseases using lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity: Experimental research",
abstract = "Peripheral blood lymphocytes (PBL) possess lectin-dependent cellular cytotoxicity (LDCC) in the presence of various lectins. In this study we showed more potent LDCC could be induced in lymphokine-activated killer (LAK) cells. Among several lectins investigated in this study pokeweed mitogen (PWM) could give LAK cells most potent and broad spectrum LDCC when LAK cells were initially stimulated by PWM. Analysis of effector cells revealed that either PBL, CD3+CD4+, CD 3+CD 8+ cells or CD3-CD56+ cells expressed manifest cytotoxicity in the presence of lectins. Both anti-HLA class I and anti-HLA class II monoclonal antibodies did not inhibit LDCC at any concentrations applied. Taken together with the former result, HLA, CD 3, CD 8 or CD 56 molecules were not relevant to LDCC. Quality and quantity of binding sites were shown to be different between effector cells and target tumor cells revealed by FACS analysis using fluorescence conjugated PWM. Mechanism of LDCC partially associated with apoptotic cell death but without NO production by effector cells. These facts suggest that more potent immunotherapy of malignant diseases might be applicable using mechanism of LDCC.",
keywords = "Immunotherapy, LAK cell, LDCC",
author = "Yasuhiko Kimoto and Minehide Lee-Miyamoto and Takai, {Shin ichiro} and Dong, {Haidong M} and Tetsuo Taguchi",
year = "1994",
doi = "10.2177/jsci.17.188",
language = "English (US)",
volume = "17",
pages = "188--198",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Treatment of malignant diseases using lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity

T2 - Experimental research

AU - Kimoto, Yasuhiko

AU - Lee-Miyamoto, Minehide

AU - Takai, Shin ichiro

AU - Dong, Haidong M

AU - Taguchi, Tetsuo

PY - 1994

Y1 - 1994

N2 - Peripheral blood lymphocytes (PBL) possess lectin-dependent cellular cytotoxicity (LDCC) in the presence of various lectins. In this study we showed more potent LDCC could be induced in lymphokine-activated killer (LAK) cells. Among several lectins investigated in this study pokeweed mitogen (PWM) could give LAK cells most potent and broad spectrum LDCC when LAK cells were initially stimulated by PWM. Analysis of effector cells revealed that either PBL, CD3+CD4+, CD 3+CD 8+ cells or CD3-CD56+ cells expressed manifest cytotoxicity in the presence of lectins. Both anti-HLA class I and anti-HLA class II monoclonal antibodies did not inhibit LDCC at any concentrations applied. Taken together with the former result, HLA, CD 3, CD 8 or CD 56 molecules were not relevant to LDCC. Quality and quantity of binding sites were shown to be different between effector cells and target tumor cells revealed by FACS analysis using fluorescence conjugated PWM. Mechanism of LDCC partially associated with apoptotic cell death but without NO production by effector cells. These facts suggest that more potent immunotherapy of malignant diseases might be applicable using mechanism of LDCC.

AB - Peripheral blood lymphocytes (PBL) possess lectin-dependent cellular cytotoxicity (LDCC) in the presence of various lectins. In this study we showed more potent LDCC could be induced in lymphokine-activated killer (LAK) cells. Among several lectins investigated in this study pokeweed mitogen (PWM) could give LAK cells most potent and broad spectrum LDCC when LAK cells were initially stimulated by PWM. Analysis of effector cells revealed that either PBL, CD3+CD4+, CD 3+CD 8+ cells or CD3-CD56+ cells expressed manifest cytotoxicity in the presence of lectins. Both anti-HLA class I and anti-HLA class II monoclonal antibodies did not inhibit LDCC at any concentrations applied. Taken together with the former result, HLA, CD 3, CD 8 or CD 56 molecules were not relevant to LDCC. Quality and quantity of binding sites were shown to be different between effector cells and target tumor cells revealed by FACS analysis using fluorescence conjugated PWM. Mechanism of LDCC partially associated with apoptotic cell death but without NO production by effector cells. These facts suggest that more potent immunotherapy of malignant diseases might be applicable using mechanism of LDCC.

KW - Immunotherapy

KW - LAK cell

KW - LDCC

UR - http://www.scopus.com/inward/record.url?scp=85007940576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007940576&partnerID=8YFLogxK

U2 - 10.2177/jsci.17.188

DO - 10.2177/jsci.17.188

M3 - Article

AN - SCOPUS:85007940576

VL - 17

SP - 188

EP - 198

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 3

ER -